Interferon alfa therapy against metastatic iris tumor of renal cell carcinoma.
نویسندگان
چکیده
Ocular metastasis of renal cell carcinoma is rare, and metastasis to the iris or ciliary body is especially uncommon. Ferry and Font studied 227 cases of metastatic tumors of the eye and orbit and reported that 26 (11.5%) of these lesions were iris or ciliary body tumors and that 2 (0.9%) originated in the kidney. We examined a patient with an iris tumor that metastasized from a renal cell carcinoma and observed marked effects of interferon alfa administration.
منابع مشابه
Metastatic Renal cell Carcinoma Presenting as a clear-cell Tumor in Tongue: A Case Report
Introduction: Metastatic lesions of the oral cavity are extremely rare, accounting for approximately 1% of all malignant oral tumors. The most common primary sources of metastatic tumors in the oral region are, from the most to the least common, the breast, lung, kidney, bone, and colon. Renal cell carcinoma accounts for nearly 3% of all adult malignancies. It usually metastasizes to the lungs,...
متن کاملInterferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial
BACKGROUND In metastatic renal cell carcinoma combinations of interferon alfa-2a, interleukin-2, and fluorouracil produce higher response rates and longer progression-free survival than do single agents. We aimed to compare overall survival in patients receiving combination treatment or interferon alfa-2a. METHODS RE04/30012 was an open-label randomised trial undertaken in 50 centres across e...
متن کاملManagement of renal cell carcinoma.
Surgical resection remains the cornerstone of management for localized renal cell carcinoma. No effective postsurgical adjuvant therapy has been established for patients with locally advanced disease who are at high risk for recurrence. The effective treatment of metastatic kidney cancer remains a challenge. Immunologic therapy with cytokines, such as interferon-alfa (Intron A, Roferon-A) and i...
متن کاملCurrent status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.
Interleukin-2 (IL-2, Proleukin) is one of the most effective agents in the treatment of metastatic renal cell carcinoma and metastatic melanoma. High-dose IL-2 therapy produces overall response rates of 15% to 20%; however, it is associated with significant toxicities that affect essentially every organ system. Although IL-2-related toxicities are usually reversible with therapy discontinuation...
متن کاملBevacizumab for renal cell carcinoma, glioblastoma, and other solid tumors.
Indications Renal cell carcinoma In July 2009, the US Food and Drug Administration (FDA) granted approval for use of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Avastin) in combination with interferon alfa for treatment of patients with metastatic renal cell carcinoma (RCC). Approval was based on results from the BO17705 trial, which demonstrated a 5-month improvement i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Archives of ophthalmology
دوره 118 6 شماره
صفحات -
تاریخ انتشار 2000